In this article the diagnosis osteonecrosis of jaws and its managementhave been reviewed. of bisphosphonate related
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Bisphosphonates, which are widely usedfor the treatment of osteoporosis, are alsoused for reducing hypercalcemia due tobone malignancies, for preventing bonemetastases of breast and prostate carcinoma and for the treatment of osteolyticlesions in multiple myeloma.
📊
Key Findings & Data:The beneficialrole of bisphosphonates in the target diseases is indisputable; however, during orafter the medication undesired side-effectsmay be seen especially in the jaw bones.Although many cases of bisphosphonaterelated osteonecrosis of jaws are associated with intravenous use of bisphosphonates, there is also evidence that jawosteonecrosis may occur with oral bisphosphonate treatment.
💡
Conclusion & Impact:In this article the diagnosis osteonecrosis of jaws and its managementhave been reviewed. of bisphosphonate related
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Bisfosfonat · Maksilla · Mandibula
Abstract
Bisphosphonates, which are widely usedfor the treatment of osteoporosis, are alsoused for reducing hypercalcemia due tobone malignancies, for preventing bonemetastases of breast and prostate carcinoma and for the treatment of osteolyticlesions in multiple myeloma. The beneficialrole of bisphosphonates in the target diseases is indisputable; however, during orafter the medication undesired side-effectsmay be seen especially in the jaw bones.Although many cases of bisphosphonaterelated osteonecrosis of jaws are associated with intravenous use of bisphosphonates, there is also evidence that jawosteonecrosis may occur with oral bisphosphonate treatment. In this article the diagnosis osteonecrosis of jaws and its managementhave been reviewed. of bisphosphonate related
Üstün, Y., Erdoğan, Ö. (2007). Diagnostic and Theraupeutic Approaches to Bisphosphonate- Related Osteonecrosis of the jaw. ADO Klinik Bilimler Dergisi, Cilt: 1 Sayı: 3, 37–42. https://ajindex.com/articles/1440750
Fleisch H, Russell RG, Francis MD. Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo.
Science. 165(899):1262-4, 1969.
Hellstein JW, Marek CL, Pharm BS. Bisphosphonate osteo- chemonecrosis (bis-phossy jaw): is this phossy jaw of the 21stcentury? J Oral Maxillofac Surg. 63:682-9, 2005.
Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonateinduced exposed bone (osteonecro- sis/osteopetrosis) of the jaws: Risk factors, recognition, prevention and treatment. J Oral Maxillofac Surg.63:1567-75, 2005.
American Association of Oral and Maxillofacial Surgeons Position Paper on Bisphosphonate-Related Osteonecrosis of the Jaws, Approved by the Board of Trustees,2006, Web
on_papers/osteonecrosis.pdf
Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff S. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg. 62:527-34, 2004.
Migliorati CA, Schubert MM, Petersen DE, Seneda LM. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone. An emerging oral complication of supportive cancer therapy. Cancer. 104:83-93, 2005.
Dimitrakopoulos I, Magopoulos C, Karakasis D. Bisphosphonate-induced avascular osteonecrosis of the jaws: a clinical report of 11 cases. Int. J. Oral Maxillofac. Surg. 35: 588–593, 2006.
Farrugia MC, Summerlin DJ, Krowiak E, Huntley T, Freeman S, Borrowdale R, Tomich C. Osteonecrosis of the Mandible or Maxilla Associated with the use of New Generation Bisphosphonates. Laryngoscope. 116(1):115- 20, 2006.
Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonateinduced exposed bone (osteonecro- sis/osteopetrosis) of the jaws: Risk factors, recognition, prevention and treatment. J Oral Maxillofac Surg. 63:1567-75, 2005
) Durie BGM, Katz M, Crowley J. Osteonecrosis of the jaws and bisphosphonates. N Engl J Med. 353:99, 2005.
) Bamias A, Kastritis E, Bamia C, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: inci- dence and risk factors. J Clin Oncol. 23:8580-7, 2005.
) Badros A, Weikel D, Salama A. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk fac- tors. J Clin Oncol. 24:945-52, 2006.
) Hoff AO, Toth BB, Altundag K, et al. Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate the- rapy. J Clin Oncol. 24:8528, 2006.
) Ruggiero SL, Fantasia J, Carlson E. Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Path Oral Radiol Endod. 102(4):433-41, 2006.
) Andrade C, Martinez A, Walker S. Comparative Safety Evaluation of Non-narcotic Analgesics?. Journal of Clinical Epidemiology, 51(12):1357-1365, 2006.
) Slatkin N. Cancer-related pain and its pharmacologic management in the patient with bone metastasis. J Support Oncol. 4(2):15-21, 2006.
) Lin JH.Bisphosphonates: a review of their pharmacokinetic properties.